Adenoid Cystic Carcinoma Epidemiology

Key Highlights

 

• According to Calderón Boyle et al. (2020) in the US, Adenoid Cystic Carcinoma incidence rate was 0.35 per 100,000. Adenoid Cystic Carcinoma limited duration prevalence was highest in those aged 75-79 years and in females, and lowest among Native Americans/Alaska Natives. Adenoid Cystic Carcinoma cases were highest in the oral cavity and pharynx.

 

• A multicenter Baujat et al. (2020), the across Europe average age for Adenoid Cystic Carcinoma was 55 years and females accounted for 59.4% of the cohort. The body mass index (BMI) was normal in 86% of cases while tumor was located in minor salivary glands in 60% of cases. T3/T4 stages represented 58%; 89% of patients and histological grade III was observed on 21% of patients. The EFS and overall 5-year survival rates were 50% and 85%, respectively. 

 

• According to Inagaki et al. (2020) study of Adenoid Cystic Carcinoma cases of salivary gland origin in Japan, 5-year overall survival (OS) and disease-free survival (DFS) rates were 92.5% and 50.0%, respectively with treatment failure in 46% cases while distant failures in 34%.

 

• Adenoid Cystic Carcinoma epidemiology is segmented as Total Incident Cases of Adenoid Cystic Carcinoma, Gender-specific Cases of Adenoid Cystic Carcinoma, Grade-specific Cases of Adenoid Cystic Carcinoma, and Treatable Cases of Adenoid Cystic Carcinoma] in the Adenoid Cystic Carcinoma epidemiology report.

 

Request a sample to unlock the CAGR for Adenoid Cystic Carcinoma Epidemiology

 

DelveInsight's ‘Adenoid Cystic Carcinoma Epidemiology Forecast — 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Adenoid Cystic Carcinoma epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

 

Study Period: 2021-2034

 

Adenoid Cystic Carcinoma Epidemiology: Understanding

The DelveInsight’s Adenoid Cystic Carcinoma market report gives a thorough understanding of Adenoid Cystic Carcinoma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Adenoid cystic carcinoma is a rare form of adenocarcinoma that begins in the glandular tissues. It commonly develops in the salivary glands or other regions of the head and neck but can also occur in other parts of the body, such as the breast, skin, cervix in females, prostate gland in males, etc. Adenoid cystic carcinoma tumors are characterized by a distinctive histological pattern of abnormal “nests” or cords of epithelial cells that surround or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes, apparent during the microscopic evaluation of tumor cells.

 

Signs & symptoms depend largely on the site of origin of the tumor. Early lesions of the salivary glands are present as painless masses of the mouth or face, usually growing slowly. Advanced tumors result in pain and nerve paralysis. Tumors of the lacrimal gland present as proptosis and changes in vision while ACC arising in the tracheobronchial tree may have respiratory symptoms, and those in the larynx may lead to changes in speech.

 

Adenoid Cystic Carcinoma Diagnosis

The diagnosis is made by histological analysis of a biopsy or specimen of a tumor mass. There are no serum markers for this neoplasm. Recurrences are usually identified by radiographic imaging techniques, such as computed tomography, MRI, and PET scan. There are three tumor growth patterns common to ACC: cribriform, tubular, and solid. Cribriform is most common while cribriform and tubular both are less aggressive. The WHO has classified Adenoid cystic carcinoma into Grade I, II and III based on these forms.

 

The exact cause of adenoid cystic carcinoma is unknown. Researchers speculate that a protein produced by MYB-NFIB plays a role in the development of ACC tumors. There is a slight female preponderance and it is staged using the TNM system for salivary gland tumors.

 

Adenoid Cystic Carcinoma Epidemiology 

The Adenoid Cystic Carcinoma epidemiology section provides insights about historical and current Adenoid Cystic Carcinoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

 

• According to Calderón Boyle et al. (2020) in the US, Adenoid Cystic Carcinoma incidence rate was 0.35 per 100,000. Adenoid Cystic Carcinoma limited duration prevalence was highest in those aged 75-79 years and in females, and lowest among Native Americans/Alaska Natives. Adenoid Cystic Carcinoma cases were highest in the oral cavity and pharynx.

 

• A multicenter Baujat et al. (2020), the across Europe average age for Adenoid Cystic Carcinoma was 55 years and females accounted for 59.4% of the cohort. The body mass index (BMI) was normal in 86% of cases while tumor was located in minor salivary glands in 60% of cases. T3/T4 stages represented 58%; 89% of patients and histological grade III was observed on 21% of patients. The EFS and overall 5-year survival rates were 50% and 85%, respectively. 

 

• According to Inagaki et al. (2020) study of Adenoid Cystic Carcinoma cases of salivary gland origin in Japan, 5-year overall survival (OS) and disease-free survival (DFS) rates were 92.5% and 50.0%, respectively with treatment failure in 46% cases while distant failures in 34%.

 

• The disease epidemiology covered in the report provides historical as well as forecasted Adenoid Cystic Carcinoma epidemiology [segmented as Total Incident Cases of Adenoid Cystic Carcinoma, Gender-specific Cases of Adenoid Cystic Carcinoma, Grade-specific Cases of Adenoid Cystic Carcinoma, and Treatable Cases of Adenoid Cystic Carcinoma] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

 

Country Wise- Adenoid Cystic Carcinoma Epidemiology

This section provides a glimpse of the Adenoid Cystic Carcinoma epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

KOL- Views

To keep up with the current Adenoid Cystic Carcinoma patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Adenoid Cystic Carcinoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

 

Learn how the therapeutic market will evolve and grow in the coming years: Adenoid Cystic Carcinoma Market
 

Scope of the Adenoid Cystic Carcinoma Epidemology Report

• The report covers the descriptive overview of Adenoid Cystic Carcinoma, explaining their causes, symptoms, pathophysiology, and genetic basis
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan
• The report assesses the disease risk and burden and highlights the unmet needs of Adenoid Cystic Carcinoma
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Adenoid Cystic Carcinoma, Gender-specific Cases of Adenoid Cystic Carcinoma, Grade-specific Cases of Adenoid Cystic Carcinoma, and Treatable Cases of Adenoid Cystic Carcinoma

 

Adenoid Cystic Carcinoma Epidemiology Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Adenoid Cystic Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Adenoid Cystic Carcinoma 
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed Adenoid Cystic Carcinoma clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Adenoid Cystic Carcinoma Report Insights

• Patient Population
• Therapeutic Approaches

 

Adenoid Cystic Carcinoma Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Adenoid Cystic Carcinoma Epidemiology Segmentation

 

Adenoid Cystic Carcinoma Report Assessment

• Disease Understanding
• Current Diagnosis Practices and Guidelines
• Epidemiology Trends

 

Key Questions

 

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Adenoid Cystic Carcinoma?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Adenoid Cystic Carcinoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Adenoid Cystic Carcinoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Adenoid Cystic Carcinoma?
• Out of all 7MM countries, which country would have the highest incident population of Adenoid Cystic Carcinoma during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?

 

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Adenoid Cystic Carcinoma Disease market
• To understand the future market competition in the Adenoid Cystic Carcinoma Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Adenoid Cystic Carcinoma Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Adenoid Cystic Carcinoma Disease market
• To understand the future market competition in the Adenoid Cystic Carcinoma Disease market